Celecoxib During Radiotherapy for Triple-Negative Breast Cancer
Tests whether celecoxib given during radiotherapy helps in adults with early triple-negative breast cancer.
Plain-language title generated from the registry record
Registry title: Triple Negative Breast Cancer and Celecoxib. Pilot Study
Key facts
- Where
- Sherbrooke, CanadaSee the site
- Phase
- Phase 2
Where in Canada
- Faculty of medicine and health sciencesSherbrooke, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Université de Sherbrooke
- Trial code
- NCT07104266
- Record updated
- 5 August 2025
- Original description
Relapses occur in 20 to 30% of patients with early-stage triple-negative breast cancer (TNBC), which is characterized by the absence of three receptors: the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2). Radiotherapy (RT) can increase or decrease, depending on the patient, the level of cytokines that promote metastasis development. To help prevent the development of metastasis, the cyclooxygenase-2 (COX-2) inhibitor celecoxib will be administered during RT. This treatment aims to prevent RT-induced cytokine increases and, ultimately, improve patient prognosis.Read full original descriptionShow less
Determine Whether Administering Celecoxib During Radiotherapy Can Reduce the Risk of Recurrence of Triple-negative Breast Cancer. Pilot Study
Relapses occur in 20 to 30% of patients with early-stage triple-negative breast cancer (TNBC), which is characterized by the absence of three receptors: the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2). Radiotherapy (RT) can increase or decrease, depending on the patient, the level of cytokines that promote metastasis development. To help prevent the development of metastasis, the cyclooxygenase-2 (COX-2) inhibitor celecoxib will be administered during RT. This treatment aims to prevent RT-induced cytokine increases and, ultimately, improve patient prognosis.
The primary objective of this pilot study is to assess the feasibility of recruiting participants and implementing the study steps, with the intention of conducting a large-scale study in the future. The secondary objective is to evaluate celecoxib ability to inhibit the RT-induced stimulation of cytokines associated with metastasis development. This will be assessed by comparing the levels of these cytokines in plasma samples collected before, during, and after RT. In the exploratory objective, TNBC cells will be incubated in vitro with these plasma samples to determine whether administering celecoxib during RT can prevent increased cancer cell invasion and metastasis formation in mice.
Inclusion: Female; Age: 18 years or older; Tumor stage: Early; TNBC status confirmed by pathology; Regional lymph node N0 to N3; No evidence of distant metastasis; Primary tumor removed by conservative surgery with negative margins.
Exclusion: Participants will be excluded if they have experienced any of the following conditions in the last six months:; Stomach ulcer; Kidney disease: Glomerular filtration rate lower than 50 mL/min; Participants taking an NSAID for another medical condition or as needed before starting their radiotherapy treatment; Participants who have demonstrated:; Hypersensitivity to celecoxib; A history of allergic reactions to sulfonamides; A history of asthma attacks, urticaria, or allergic reactions after taking acetylsalicylic acid or another nonsteroidal anti-inflammatory drug; The presence of inflammatory bowel disease; Liver disease: Aspartate aminotransferase / Alanine aminotransferase - 3 times the upper limit of normal, Bilirubine - 2 times the upper limit of normal, INR - 1.3 times the upper limit of normal, Cirrhose Child-Pugh B or more; Congestive heart failure: Left ventricular ejection fraction lower than 50%; Proven hyperkalemia.